Moreover, 40% of patients diagnosed with NDM are responsive to oral sulfonylureas (SUs) due to expressed mutations of the ABCC8 or KCNJ11 genes coding for adenosine triphosphate (ATP)-sensitive potassium channel (KATP) subunits in pancreatic beta (β) cells. This evidence concerns the gene ABCC8 and neonatal diabetes mellitus.